← Back to patent-cliff list
Piroxicam/β-Cyclodextrin
Tier C — Watch / tradePiroxicam/β-Cyclodextrin
-
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COXs
Indications (approved)：Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis
Regional status
US
-
EU
-
China
Approved
2013-12-02
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Piroxicam/β-Cyclodextrin?
Approved indications include: Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis.
When does the Piroxicam/β-Cyclodextrin patent expire?
No public expiry year is available for Piroxicam/β-Cyclodextrin yet; this page updates once verified.
How do I get a quote for Piroxicam/β-Cyclodextrin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27